Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5662060 | 0.98 | HRH3 (0.72) | HRH3HRH1CYP2D6 | |
| SCHEMBL5665130 | 0.87 | HRH3 (0.70) | HRH3HRH1CYP2D6 | |
| SCHEMBL5662733 | 0.85 | HRH3 (0.73) | HRH3HRH1CYP2D6 | |
| SCHEMBL5661966 | 0.83 | HRH3 (0.73) | HRH3HRH1CYP2D6 | |
| SCHEMBL5660371 | 0.83 | HRH3 (0.48) | HRH3HRH1 | |
| SCHEMBL3081460 | 0.82 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL5663502 | 0.81 | HRH3 (0.46) | HRH3HRH1CYP2D6MLNR | |
| SCHEMBL5170881 | 0.80 | GPR119 (0.48) | HRH3HRH1 | |
| SCHEMBL5662176 | 0.76 | HRH3 (0.66) | HRH3HRH1CYP2D6MLNR | |
| Hydrochloric Acid SCHEMBL5662921 | 0.75 | HRH3 (0.65) | HRH3HRH1CYP2D6MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885HRH1 3/4885CYP2D6 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.